Graduate Program, Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás – IPTSP/UFG.
J Bras Pneumol. 2013 Jan-Feb;39(1):76-83. doi: 10.1590/s1806-37132013000100011.
To describe the rates of cure, treatment failure, and treatment abandonment obtained with the basic regimen recommended by the Brazilian National Ministry of Health (rifampin, isoniazid, pyrazinamide, and ethambutol for two months, followed by isoniazid and rifampin for four months) involving the use of fixed-dose combination tablets (self-administered treatment), as well as to describe adverse events and their potential impact on treatment outcomes.
This was a descriptive study based on prospective data obtained from the medical records of tuberculosis patients (> 18 years of age) treated with the basic regimen at either of two primary health care facilities in the greater metropolitan area of Goiânia, Brazil.
The study sample comprised 40 tuberculosis patients. The rate of cure was 67.5%, the rate of treatment abandonment was 17.5%, and there were no cases of treatment failure. Of the 40 patients in the sample, 19 (47%) reported adverse reactions, which were mild and moderate, respectively, in 87% and 13% of the cases. It was not necessary to alter the regimen or discontinue the treatment in any of the cases evaluated.
The rate of cure obtained with the self-administered, fixed-dose combination tablet form of the new basic regimen was similar to the historical rates of cure obtained with the previous regimen. The rate of treatment abandonment in our sample was much higher than that considered appropriate (up to 5%).
描述巴西卫生部推荐的基本方案（利福平、异烟肼、吡嗪酰胺和乙胺丁醇治疗 2 个月，然后异烟肼和利福平治疗 4 个月）的治愈率、治疗失败率和治疗中断率，该方案涉及使用固定剂量联合片剂（自我管理治疗），并描述不良反应及其对治疗结果的潜在影响。
这是一项基于巴西戈亚尼亚大都市地区两个初级保健机构中使用基本方案治疗的肺结核患者（>18 岁）的病历前瞻性数据的描述性研究。
研究样本包括 40 名肺结核患者。治愈率为 67.5%，治疗中断率为 17.5%，无治疗失败病例。在样本中的 40 名患者中，有 19 名（47%）报告了不良反应，分别有 87%和 13%的病例为轻度和中度不良反应。在评估的所有病例中，均无需改变方案或中断治疗。
新基本方案的自我管理、固定剂量联合片剂形式的治愈率与之前方案的历史治愈率相似。我们样本中的治疗中断率远高于被认为是适当的（高达 5%）。
